Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong KongArticle Published on 2022-04-012023-07-07 Journal: Respirology (Carlton, Vic.) [Category] COVID19(2023년), [키워드] BioNTech BNT162b2 CoronaVac coronavirus disease COVID-19 immunogenicity SARS-CoV-2 Sinovac [DOI] 10.1111/resp.14191 PMC 바로가기
Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile완전한 CoronaVac 백신 접종 계획을 가진 환자에서 SARS-CoV-2 B.1.621(Mu) 변종 감염으로 인한 증상 설명: 칠레 산티아고의 첫 사례 보고Case Reports Published on 2022-03-212022-09-11 Journal: Frontiers in Public Health [Category] SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration appearance Asymptomatic B.1.621 Case report clinical symptom Clinical symptoms Comorbidity Complete CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 description discharge dose Evidence genomic Genomic surveillance greater Hospitalized Immunity inactivated Inactivated SARS-CoV-2 vaccine Infection Invasive mechanical ventilation life lung damage manifestation mechanical ventilation Mild pandemic Patient patients presenting Prevalence protective effect Protective effects Registered report required SARS-CoV-2 SARS-CoV-2 B.1.621 variant Science severe acute respiratory syndrome Coronavirus Sinovac Symptom Symptoms the disease the SARS-CoV-2 vaccination schedule Vaccine vaccine administration Vaccines variant [DOI] 10.3389/fpubh.2022.797569 PMC 바로가기 [Article Type] Case Reports
What causes COVID-19 vaccine hesitancy? Ignorance and the lack of bliss in the United Kingdom Research Published on 2022-03-172022-10-05 Journal: Humanities & Social Sciences Communications [Category] 임상, 치료법, [키워드] Anxiety cause Chinese COVID-19 pandemic COVID-19 vaccine Critical globe Government healthcare ignorance increasingly individual lack Medicare Population produced protocols Sinovac Theranos understanding United Kingdom vaccination Vaccine Vaccine hesitancy Vaccines [DOI] 10.1057/s41599-022-01092-w [Article Type] Research
Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac’s CoronaVac or AstraZeneca/Oxford’s AZD1222 SARS-CoV-2 vaccinesSinovac의 CoronaVac 또는 AstraZeneca/Oxford의 AZD1222 SARS-CoV-2 백신 2회 투여 후 수용체 결합 도메인-ACE2 상호작용 억제Article Published on 2022-03-012022-09-12 Journal: Journal of medical virology [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome angiotensin-converting enzyme-2 antibodies antibody Antibody Response assays association AZD1222 binding CoronaVac coronavirus COVID-19 decrease domain dose Efficacy elicited enzyme evaluate evaluated facilitate identify incidence individuals inhibit inhibition inhibitory Interaction interquartile range IQR Laboratory median natural infection Population postvaccination prevaccination RBD reactivity receptor Receptor-binding domain robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine second dose serological Sinovac subjects trials Vaccine vaccinees viral neutralization [DOI] 10.1002/jmv.27396 PMC 바로가기 [Article Type] Article
Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real worldSARS-COV-2를위한 자동 화학 발광 면역 플랫폼의 성능 평가 현실에서 예방 접종 후 항체Research Published on 2022-02-152022-09-01 Journal: BMC Infectious Diseases [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단, [키워드] Adolescent BBIBP-CorV changes in Characteristics chemiluminescence China CLIA Cohort CoronaVac doses evaluated exceeded Follow-up followed by Hemolysis high correlation icterus immune immunity after vaccination immunoassays inactive injection inoculation investigated less linearity lipemia measure Neutralizing activity Neutralizing antibodies neutralizing antibody objective occurred performance Physical examination Plaque reduction neutralization test platform predominant PRNT Real world recipient recruited repeatability Result robust SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccine schedule Sensitivity and specificity Serological assay serological assays seropositive Shenzhen significantly lower Sinovac strength Trial vaccination Vaccination Status Vaccinations Vaccine Variation volunteers [DOI] 10.1186/s12879-022-07141-8 PMC 바로가기 [Article Type] Research
Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival중환자실 생존에 대한 비활성화된 SARS-CoV-2 백신(CoronaVac)의 효과Original Paper Published on 2022-02-092022-09-11 Journal: Epidemiology and Infection [Category] COVID19(2023년), MERS, SARS, 변종, [키워드] Admission admitted to ICU arterial blood arterial blood gas Blood blood gas clinical CoronaVac coronavirus disease Coronavirus disease 2019 Course COVID-19 eligible enrolled evaluated ferritin ferritin level ferritin levels genetic variants group had no hospital Hospital mortality Hospital stay ICU inactivated intensive care intensive care unit investigated Laboratory Lactate lactate dehydrogenase Length Mortality National no effect not different on admission parameters Patient patients protective effect radiological Radiological parameters SARS-CoV-2 pandemic SARS-CoV-2 vaccine Sinovac survival target population vaccination vaccination schedule Vaccine [DOI] 10.1017/S0950268822000267 PMC 바로가기 [Article Type] Original Paper
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종Clinical Trial Published on 2022-02-052022-08-13 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술, [키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine [DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies질병 조절 요법으로 치료받은 다발성 경화증 환자에서 mRNA와 불활성화 백신 2회 투여 후 SARS-CoV-2 항체 반응의 비교Article Published on 2022-02-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Antibody titer BNT162b2 collected COVID-19 cross-sectional decrease Disease-modifying therapy dose greater healthy controls immune response immune system inactivated Inactivated vaccine Messenger RNA mRNA mRNA vaccine Multiple multiple sclerosis participant patients treated Pfizer/BioNTech Protective risk SARS-CoV-2 SARS-CoV-2 antibody second dose seronegative serum sample significant difference single-center Sinovac the vaccine therapy treated Treatment untreated patient Vaccine vaccine group Vaccines [DOI] 10.1016/j.msard.2022.103486 PMC 바로가기 [Article Type] Article
Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group건강한 인구집단에서 CoronaVac 28일 일정 예방접종으로 유도된 면역 반응 평가Immunology Published on 2022-01-312022-09-11 Journal: Frontiers in Immunology [Category] 바이오마커, 진단, [키워드] administration Analysis anti-spike antibodies anti-spike antibody Cell cellular Cellular immune response cellular immune responses CoronaVac COVID-19 Effectiveness ELISPOT evaluate granzyme granzyme B group herd immunity Hospitalization humoral immune response IFN-gamma immune memory immune response immune responses immunization Immunological memory increase in induce induced life memory Negative PCR Neutralizing Neutralizing antibodies Population recruited response robust SARS-CoV-2 SARS-CoV-2 spike protein schedule Science Sinovac Spike protein vaccination schedule Vaccine Volunteer [DOI] 10.3389/fimmu.2021.766278 PMC 바로가기 [Article Type] Immunology
Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case seriesCase Report Published on 2022-01-212022-10-29 Journal: The Journal of Headache and Pain [Category] Coronavirus, [키워드] abnormality aluminum attack Brain case sery change characteristic CoronaVac CoronaVac vaccine Cortical spreading depression COVID-19 COVID-19 vaccination female functional headache inactivated Inflammation Injury migraine motor deficits neurological Neurological deficit Neurological symptom Neurological symptoms occurred Pain pathophysiology Patient patients predominant Prolonged receiving Region Sinovac stroke supplementary material susceptible patients symptomatic Symptoms syndrome vaccination Vaccine vaccine injection virus [DOI] 10.1186/s10194-022-01385-0 PMC 바로가기 [Article Type] Case Report